Eidos Therapeutics
BiotechnologyView the employees at
Eidos Therapeutics-
Satish Rao Senior Vice President of DMPK at Eidos Therapeutics
-
San Francisco Bay Area
-
Top 5%
Shane McAllister Associate Director of Supply Chain and Logistics at Eidos Therapeutics-
Greater St. Louis
-
Rising Star
Suresh Siddhanti Vice President, Clinical Development at Eidos Therapeutics-
San Francisco Bay Area
-
Rising Star
Matt Masek Senior Manager, Quality Assurance at Eidos Therapeutics-
Livonia
-
Rising Star
Melissa Jensik Director, Quality Assurance at Eidos Therapeutics-
Waltham, Massachusetts, United States
-
Rising Star
Overview
Eidos Therapeutics, a subsidiary of BridgeBio Pharma, is developing AG10 as a targeted therapeutic for transthyretin amyloidosis. The company’s singular mission is to improve and prolong the lives of patients suffering from this disease. Launched in 2016 after years of research supported by Stanford’s SPARK program, Eidos is led by a team of veteran biotechnology executives. Together with patients and physicians, the company aims to bring a safe, effective treatment to market as quickly as possible.
-